Ribon Therapeutics
2015
FOUNDED
PRIVATE
STATUS
41-50
EMPLOYEES
Series B
LATEST DEAL TYPE
$65M
LATEST DEAL AMOUNT
10
INVESTORS
Description
Developer of a biotech platform intended to block cancer cell's fundamental ability to survive under stress. The company's offerings include discovery and development of first-in-class small molecule inhibitors or each enzyme in the target family, enabling doctors to help treat patients suffering from cancer.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 35 Cambridgepark Drive
- Cambridge, MA 02140
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ribon Therapeutics’s full profile, request a free trial.
Ribon Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 04-Jan-2019 | $65M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 1. Early Stage VC (Series A) | 10-Oct-2017 | 000.00 | 000.00 | 000.00 | Completed | Stealth |
Ribon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Ribon Therapeutics Competitors (36)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN | 00 | 000.00 | 0000000000 0 | 000.00 |
| 00000000000 | Angel-Backed | Culver City, CA | 00000 | 000000000000 | 00000 | |
| 00000000 | Venture Capital-Backed | Uppsala, Sweden | 00 | 0000000000 | ||
| 0000000000 0000000 | Venture Capital-Backed | Seattle, WA | 00 | 0000 | 00000000000 | 0000 |
| 00000 000000000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 000000000000 | 000.00 |
Ribon Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Celgene | Corporation | Minority | 000 0000 | 000000 0 | ||
| Johnson & Johnson Innovation - JJDC | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 |
Ribon Therapeutics Executive Team (10)
1 Former Executive
You’re viewing 5 of 10 executives. Get the full list »Ribon Therapeutics Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Anja König Ph.D | Novartis Venture Fund | Board Member | 000 0000 | |
| Cameron Wheeler Ph.D | Deerfield Management | Board Member | 000 0000 | |
| James Audia Ph.D | Self | Board Member | 000 0000 | |
| Jonathan Root MD | US Venture Partners | Board Member | 000 0000 | |
| Laurence Lasky Ph.D | The Column Group | Board Member | 000 0000 |